Please login to the form below

DLBCL

This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness. ... population in Europe, which could give Gilead space to establish itself in DLBCL in these markets.

Latest news

Gilead optimistic about Yescarta deal in UK

The CAR-T production process. DLBCL will be the competitive battleground for Novartis and Gilead, and there’s no doubt Yescarta has the upper hand at this early stage. ... It has significantly better response rates in DLBCL than Kymriah: its overall
Novartis’ CAR-T Kymriah gets green light in England

at the same time as Kymriah in Europe for adults with DLBCL and primary mediastinal large B-cell lymphoma (PMLBL). ... That might suggest Novartis will have a tougher time when it comes to the adult DLBCL indication for Kymriah.
It’s a no for Yescarta, says NICE on heels of EU approval

mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.”It’s been estimated there are around 4, 800 people are diagnosed with DLBCL or PMLBL each year
Novartis and Gilead's rival CAR-Ts approved in Europe, but supply capacity in question

in second or later relapse, and also for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ... Nevertheless, Novartis’staggered roll-out gives Gilead a free run at the DLBCL market for the time being.
Celgene’s Revlimid gets a win in late-stage lymphoma

An earlier read-out in diffuse large B-cell lymphoma (DLBCL) also missed the mark. ... plus chemo in first-line (DLBCL) – could generate $273m for Celgene in 2020.

More from news
Approximately 6 fully matching, plus 39 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party
Deal Watch January 2018

The company switched focus to its JCAR017 programme and recently reported promising data in a pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl
Pharma deals in April 2015

its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.
Current development and marketing of biosimilar monoclonal antibodies in Latin America

Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

Celgene boosts CAR-T stake again with Bluebird Bio deal

That deal gave it rights to Juno’s lead CAR-T candidate JCAR017 (lisocabtagene maraleucel), which is in testing for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), as

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writer - Creative and Scientific Projects: DOE

Sudler London - Senior Medical Writer: Competitive

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Writer, Healthcare Advertising, London: Excellent package

Senior Training Manager - Surrey: Competitive Salary &Bonus

Account Manager- 4 days per week or full-time: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Manager: Negotiable

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Medical Writer: Salary is DOE

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Healthcare PR Senior Account Manager: Salary TBC

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Director, Healthcare Advertising Agency: Salary TBC

Healthcare PR Director: £100, 000 – £120, 000 benefits

Sudler London - Account Director: Competitive

Subscribe to our email news alerts

PMHub

Add my company

Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....